Group 1 - The company Haike Xinyuan (SZ 301292) announced that its 21st second board meeting will be held on October 24, 2025, to review the proposal for the "2025 Q3 Report" [1] - For the first half of 2025, Haike Xinyuan's revenue composition is entirely from the manufacturing of chemical raw materials and chemical products, accounting for 100.0% [1] - As of the report date, Haike Xinyuan has a market capitalization of 5.8 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year, indicating a hot secondary market in biomedicine [1] - Despite the thriving secondary market, the primary market is facing challenges in fundraising, as noted by investor Lu Gang from Chuangdong Investment [1]
海科新源：10月24日召开董事会会议